In a significant stride towards advancing cancer research and drug development, the European Organisation for Research and Treatment of Cancer (EORTC) has joined forces with the European Medicines Agency (EMA) in a groundbreaking collaboration. This strategic partnership aims to foster innovation, streamline processes, and accelerate the translation of scientific discoveries into effective cancer treatments.
The first half of 2024 will see an extraordinary series of workshops where EORTC and EMA will work hand in hand to address the many challenges of clinical research: from ultra-rare cancers to quality of life and treatment optimisation.
By fostering synergies between academic research and regulatory processes, this partnership aims to accelerate the delivery of new and effective cancer treatments to patients across the European Union.
Denis Lacombe, EORTC CEO expressed immense enthusiasm about this series of workshops: “This unique collaboration is a remarkable testament to the shared commitment of EORTC and EMA to advancing cancer research. By combining our expertise, we aim to overcome hurdles and accelerate the development of innovative and effective therapies for the benefit of patients.”
The collaborative efforts of EORTC and EMA are expected to pave the way for a more harmonised and efficient landscape in cancer research and drug development, offering renewed hope for patients and further establishing Europe as a leader in the global fight against cancer.